Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
about
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategiesResistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase geneSerine, glycine and one-carbon units: cancer metabolism in full circleSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesProdrugs of phosphonates and phosphates: crossing the membrane barrierTargeting Hsp90 in urothelial carcinomaDynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside AntimetabolitesInteraction between DNA Polymerase and Anticancer Nucleoside AnalogsWEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II studyAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyCombination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expressionInhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeuticsPharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studiesA randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignanciesThrombocytosis in patients with pancreatic cancer treated with gemcitabine - does it have clinical significance? Description of 6 casesGlycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapyHigh-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesThe increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy.Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modificationPharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphismGemcitabine-induced cardiomyopathy: a case report and review of the literature.Regulatory functional territory of PLK-1 and their substrates beyond mitosis.Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.Antitumor activity of a novel antisense oligonucleotide against Akt1.Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patientsSynergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro.Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.PharmGKB summary: gemcitabine pathwayDeoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals.Modulating DNA methylation in activated CD8+ T cells inhibits regulatory T cell-induced binding of Foxp3 to the CD8+ T Cell IL-2 promoterA case of late-onset gemcitabine lung toxicityRedox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer.Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck.
P2860
Q24645225-2E15E46F-E7AA-49E5-A983-19585DB2F818Q24794747-F35DB7BF-46C6-48F5-9513-B2085D36F992Q26828610-BE1C2300-7CC6-4E90-BE08-5A2A92DB1679Q26830695-9A8981D5-6366-4C32-97A9-1F7102F5E40FQ27004292-B78AFD69-3899-43FE-B039-BDF88E84028BQ27005712-C867715A-672E-4CE7-ADA4-AB39F0F63AFFQ27023406-30DD4637-1081-4C27-AE48-83BCF74A87C8Q27485663-2C4AFFE6-2B7B-4CD1-BBC1-70D9BB246CC0Q27660350-0E6B06AF-4EB6-416D-A5BF-F79E6437D23DQ27853174-71324C21-8DF7-45F4-B52F-11073E4B3CE0Q28364203-8C120081-FA51-4356-9D2F-0EF0543E5B27Q28484288-93FE5FE9-A4B1-4A9F-BDB8-60FFB06414C4Q28485457-1653F15C-818B-41B4-AA5C-19CC45495BA3Q28487715-B0DB832A-7108-45A0-9993-082CD52AD227Q28535154-5149C436-1406-4D54-AA3D-E6B9C710A18DQ33394594-6DA03086-E493-407B-9A24-F269B830D364Q33398947-A707D317-7132-4B4C-9514-F0B4F2818815Q33408561-59752110-92AF-44F5-B130-926E2CD09C12Q33437264-2B5B64BA-4ECF-49D2-881B-57622C2AABABQ33566475-F4C0ADF0-47CB-418B-B5DF-2DF6884128D3Q33591937-CD0F8C8D-1CC1-4502-9334-6CBAA5A85E52Q33618935-E9217992-FA6D-4B4F-8662-07396A7FC388Q33733758-197BCCCF-52BB-4B82-AAAF-70B3B1F37277Q33791851-1B3CA94C-F5DE-4D5A-99C3-1EA39994DDFAQ33847161-D6E5C0CF-E413-4EFA-8DB6-984724EAF728Q33863038-F29052FF-583A-4D08-A3D8-F6F193A1580FQ33914204-6F41BF93-1C74-4792-AB68-78D84872DA0CQ33918107-B68A5146-92C9-49C9-BBD5-9C8D97B78C23Q33941641-94BAA52C-999F-42E9-A9B8-229BE9BACBFBQ34183257-A6873B30-E510-43C6-B738-CE1653BB2EC2Q34343973-F3815A7F-F71B-4C52-8BE8-AEFCCCE7B692Q34395614-86BD9851-61BB-4B65-98D5-2822AD6E50D3Q34402129-6D7A8122-26D1-4CD6-8C20-E148F2FF0E89Q34435450-84DF368E-4DB6-48D3-ACBA-15059245FE15Q34438371-4F6AC26D-4C88-4551-8468-5B329BF8F369Q34489433-AB2842A2-81A7-4C45-9B40-CE7C34F9E944Q34980150-9C671A89-0600-4F33-ADCB-227367998A13Q35052548-ECB2C681-DDA9-42AA-86AC-99D26D3ED19EQ35089242-42EC69A4-AE2F-41E2-A9EC-20CD963E7E62Q35382232-76E5D37B-021F-4469-903B-1E3466BEF0F8
P2860
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
@en
type
label
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
@en
prefLabel
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
@en
P2093
P1433
P1476
Gemcitabine: metabolism, mechanisms of action, and self-potentiation
@en
P2093
P433
4 Suppl 11
P577
1995-08-01T00:00:00Z